Anixa Biosciences
ANIX
29 hedge funds and large institutions have $11.8M invested in Anixa Biosciences in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
113% more capital invested
Capital invested by funds: $5.53M → $11.8M (+$6.23M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
32% more funds holding
Funds holding: 22 → 29 (+7)
0.43% more ownership
Funds ownership: 7.57% → 8% (+0.43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.95M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$273K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$202K |
| 4 |
Jane Street
New York
|
+$125K |
| 5 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
+$96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$311K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$147K |
| 3 |
Morgan Stanley
New York
|
-$66.1K |
| 4 |
HPCM
Hunter Perkins Capital Management
Lombard,
Illinois
|
-$54K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
26
Accel Wealth Management
Waverly,
Iowa
| $6K | +$5.97K | +1,250 | New |
|
27
JP Morgan Chase
New York
| $3K | -$1.41K | -296 | -31% |
|
|
HPCM
28
Hunter Perkins Capital Management
Lombard,
Illinois
| – | -$54K | -17,653 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$44K | -14,218 | Closed |
|
|
ASN
30
Advisory Services Network
Atlanta,
Georgia
| – | -$1K | -400 | Closed |
|
ANIX Hedge Fund Activity: Q1 2021 in Review
29 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2021, worth a combined $11.8M — up 113% from $5.53M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ANIX positions and 3 closed out — a net gain of 8 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.95M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $311K.
- 29 institutional investors held Anixa Biosciences (ANIX) as of Q1 2021, up from 22 in Q4 2020.
- Funds reported $11.8M of Anixa Biosciences stock for Q1 2021, up 113% quarter-over-quarter.
- 11 funds opened new Anixa Biosciences positions in Q1 2021 and 3 closed out, a net change of +8 holders.
- The largest Anixa Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $2.95M added.
- The largest Anixa Biosciences seller in Q1 2021 was Qube Research & Technologies (QRT), an estimated $311K sold.
Based on aggregated 13F filings for Q1 2021.